Search

Your search keyword '"Buggisch, Peter"' showing total 542 results

Search Constraints

Start Over You searched for: Author "Buggisch, Peter" Remove constraint Author: "Buggisch, Peter"
542 results on '"Buggisch, Peter"'

Search Results

1. Rare HCV subtypes and retreatment outcomes in a cohort of European DAA-experienced patients

2. A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B

3. Long-term persistence of HCV resistance-associated substitutions after DAA treatment failure

4. Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals

7. THU-386-YI Renin-angiotensin inhibitor intake is associated with improved survival in patients with chronic hepatitis C viral infection following SVR-data from the german hepatitis C-registry (DHC-R)

9. Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1–3 Infections

13. Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals

15. Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study

17. Increasing functional cure rate beyond 96 weeks after discontinuation of nucleos (t)ide analogue treatment in HBeAg-negative chronic hepatitis B: follow-up of the stop-NUC trial

18. Off-label Bulevirtide monotherapy for chronic hepatitis D virus infection in patients with decompensated liver disease

19. Improvements in ALT levels during Bulevirtide treatment for hepatitis D are seen regardless of virologic response

20. Unusual HCV subtypes and retreatment outcomes in a cohort of European DAA-experienced patients

22. Antiviral Therapy of Chronic Hepatitis D Virus Infection – Addendum to the S3 Guideline "Prophylaxis, Diagnosis and Therapy of Hepatitis B Virus Infection" of the German Society for Gastroenterology, Digestive and Metabolic Diseases (DGVS) 1.

23. Addendum „Antivirale Therapie der chronischen Hepatitis-D-Virusinfektion" zur S3-Leitlinie „Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion" der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) 1

24. Treating hepatitis D with bulevirtide – Real-world experience from 114 patients

25. Clinical characteristics of patients with non-alcoholic fatty liver disease (NAFLD) in Germany – First data from the German NAFLD-Registry

27. Post-treatment elevated gamma-glutamyl transferase is the best predictor for future outcomes in HCV patients achieving sustained virological response-data from the german hepatitis C-registry (DHC-R)

28. Effectiveness of voxilaprevir/velpatasvir/sofosbuvir in hepatitis C patients previously treated with direct-acting antiviral agents (DAA)

29. Long-term follow-up of HCV resistance-associated substitutions after DAA treatment failure

30. Randomized Controlled Trial of Danoprevir Plus Peginterferon Alfa-2a and Ribavirin in Treatment-Naïve Patients With Hepatitis C Virus Genotype 1 Infection

31. Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial

33. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study

34. Sex-specific effects of TLR9 promoter variants on spontaneous clearance of HCV infection

41. Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals

45. Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis C

46. Three-Year Efficacy and Safety of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis B

47. Real-Life Experiences with Telaprevir in the Treatment of Chronic Genotype 1 Hepatitis C — The TEPS Study

48. # 1429 Baseline factors associated with increased sustained virologic response rates in 123 treatment-naive chronic hepatitis C virus genotype 1 patients treated with a shortened 12-week simeprevir plus pegylated interferon and ribavirin regimen: A multivariate analysis

50. Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II)

Catalog

Books, media, physical & digital resources